{
    "clinical_study": {
        "@rank": "65261", 
        "arm_group": [
            {
                "arm_group_label": "Clopidogrel and Aspirin", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Copidogrel", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare pharmacokinetics between fixed-dose combination and\n      separate combination of clopidogrel 75mg/aspirin 100mg."
        }, 
        "brief_title": "Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination", 
        "completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A healthy male volunteer aged 20 to 55, and within 20% of ideal body weight.\n\n          -  Have not any congenital or chronic diseases and medical symptom.\n\n          -  Appropriate subject for the study judging from examinations(interview, vital signs,\n             12-lead ECG, physical examination, blood, urinalysis result on screening.\n\n          -  Able to participate in the entire trial.\n\n          -  Signed the informed consent form prior to study participation.\n\n        Exclusion Criteria:\n\n          -  Take metabolic enzyme inducing or inhibiting drugs like barbiturates within 28 days\n             prior to the first IP administration.\n\n          -  show evidence of acute disease within 28 days prior to the first IP administration.\n\n          -  Have the medical history of bleeding symptom or bleeding disease\n\n          -  Have the disease history(ex. Inflammatory intestinal disease, stomach or duodenum\n             ulcer, liver and bowels disease, appendectomy except of gastrointestinal surgery\n             history) that may influence on the absorption, distribution, metabolism and excretion\n             of the drug.\n\n          -  Have relevant hypersensitivity against drug or clinically significant allergic\n             diseases except mild rhinitis that does not need medication.\n\n          -  Have hypersensitivity reaction histories for Clopidogrel or aspirin.\n\n          -  Have abnormal laboratory result. AST or ALT > 1.25 times of upper limit/ Total\n             bilirubin > 1.5 times of upper limit/ PT, aPTT, BT over upper limit/ Platelet count\n             <150X10^9/L or >350X10^9/L\n\n          -  A drug abuse or a heavy caffeine consumer (more than 5cups per a day) or a heavy\n             smoker (more than 10 cigarettes per a day) or a regular alcohol consumer(more than\n             30g/day) or drinking within 7days prior to the first IP administration.\n\n          -  Have a diet(Especially, grapefruit juice-within 7days prior to the first IP\n             administration) that may influence on the absorption, distribution, metabolism and\n             excretion of the drug(s).\n\n          -  Have donated whole blood within 60 days prior to the first IP administration.\n\n          -  Participated in the other clinical trials within 90days prior to the first IP\n             administration.\n\n          -  Take medicine which affect to this trial within 10 days prior to the first IP\n             administration.\n\n          -  Appropriate subject for the trial judging from principal investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2010", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01663038", 
            "org_study_id": "119HPS10F"
        }, 
        "intervention": [
            {
                "arm_group_label": "Clopidogrel and Aspirin", 
                "description": "Clopidogrel and Aspirin separate combination, single dose", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Clopidogrel: Plavix"
            }, 
            {
                "arm_group_label": "Copidogrel", 
                "description": "Fixed dose combination of clopidogrel/aspirin", 
                "intervention_name": "Fixed dose combination of clopidogrel/Aspirin", 
                "intervention_type": "Drug", 
                "other_name": "Coprigrel"
            }, 
            {
                "arm_group_label": "Clopidogrel and Aspirin", 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug", 
                "other_name": "Aspirin: Astrix"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Ticlopidine", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Clopidogrel", 
            "Aspirin", 
            "Combination", 
            "Pharmacokinetics", 
            "Phase 1"
        ], 
        "lastchanged_date": "August 10, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pusan", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Inje University Pusan Paik Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Pharmacokinetics of Clopidogrel 75mg and Aspirin 100mg After Single Oral Administration as a Fixed Dose Combination Versus Separate Combination in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Inje University", 
            "last_name": "JH Shon, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax of clopidogrel/acetylsalicylic acid", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h"
            }, 
            {
                "measure": "AUC of clopidogrel/acetylsalicylic acid", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01663038"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assess Cmax of salicylic acid.", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h"
            }, 
            {
                "measure": "Assess AUC of salicylic acid.", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "collaborator": {
                "agency": "Inje University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}